Beyond the Neonatal Window: Regenerative and Neuromodulatory Strategies for the Injured Developing Brain
This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Special Issue Information
Dear Colleagues,
The acute neonatal window is now well covered by existing research, with therapeutic hypothermia, adjuvant neuroprotection and the first 72 h after injury having generated a large and mature body of literature. What is strikingly absent is the period that follows. Once the child leaves the neonatal unit, the relevant biology largely disappears from the literature and the discussion becomes almost entirely rehabilitative; cell and cell-free therapies, non-invasive neuromodulation and plasticity-driven training are already used in these children in practice, often ahead of the evidence. These two bodies of literature barely interact, and families are instead making decisions in that gap.
This Special Issue deliberately begins where the neonatal literature stops. It concerns children beyond the neonatal period who live with established brain injury: perinatal hypoxic–ischaemic injury presenting as cerebral palsy, acquired injury (cardiac arrest, drowning, trauma, post-infectious encephalopathy, childhood stroke), and genetic or metabolic encephalopathies with a static or slowly evolving lesion. The question it asks is biological rather than rehabilitative: months to years after the insult, what remains modifiable in the developing brain, how do we identify the children in whom it is still modifiable, and which interventions actually act on it? This Issue retains a mechanistic backbone, so that clinical contributions rest on biology rather than on descriptions of practice, which places it within the journal's scope in experimental and translational medicine rather than in rehabilitation.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- The chronic lesion: what remains biologically modifiable months to years after perinatal or acquired injury;
- Chronic neuroinflammation and microglial priming as targets beyond the acute phase;
- White matter, oligodendrocyte maturation arrest and remyelination potential in the developing brain;
- Biomarkers of residual plasticity: advanced MRI, quantitative EEG and TMS mapping as selection tools;
- Mesenchymal stromal cells in children with established cerebral palsy: what the trials have and have not shown;
- Extracellular vesicles and exosomes as cell-free therapy in the chronic phase;
- Route, dose and timing of delivery outside the acute window: intrathecal, intravenous, and intranasal;
- Non-invasive neuromodulation (rTMS, tDCS, photobiomodulation) as a plasticity primer;
- Pairing biological therapy with intensive rehabilitation: does the combination matter?;
- Outcome measures able to detect change in the chronic phase, and their ceiling effects;
- Safety, ethics and regulation of unproven regenerative treatments in children;
- Registries and real-world evidence where randomised trials are not feasible.
I look forward to receiving your contributions.
Prof. Dr. Burak Tatlı
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- developing brain
- cerebral palsy
- perinatal brain injury
- neuroplasticity
- mesenchymal stromal cells
- extracellular vesicles
- neuromodulation
- remyelination
- neuroinflammation
- paediatric neurorehabilitation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

